Capecitabine Market Forecast 2023-2032: Market Size, Drivers, And Trends

Posted by ramtbrc on November 22nd, 2023

The Capecitabine Global Market Report 2023, provides comprehensive information on the capecitabine market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.

Learn More On The Capecitabine Market’s Growth:

https://www.thebusinessresearchcompany.com/report/capecitabine-global-market-report

The global capecitabine market is expected to grow from .88 billion in 2022 to .06 billion in 2023 at a compound annual growth rate (CAGR) of 9.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global capecitabine is expected to reach .88 billion in 2027 at a CAGR of 8.8%.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=12240&type=smp

Developing novel therapies has emerged as a key trend gaining popularity in the capecitabine market. Major players operating in the capecitabine market are concentrating on creating advanced treatments in combination with capecitabine to strengthen their position in the market. For instance, in April 2020, Seagen Inc., a US-based biotechnology company, introduced TUKYSA (tucatinib), the first HER-2 tyrosine kinase inhibitor approved in combination with capecitabine and trastuzumab to treat HER2-positive metastatic breast cancer. It has anti-tumor action in HER2-positive cancer cells. When combined with the anti-HER2 antibodies trastuzumab and capecitabine, the medication demonstrated greater anti-tumor efficacy both in vivo and in vitro when compared to either treatment alone. It resulted in a verified objective response rate (ORR) of 40.6%, while trastuzumab and capecitabine alone resulted in an ORR of 22.8%.

The capecitabine market is segmented:

1) By Drug Type: Branded, Generic

2) By Drug Formulation: Tablet, Capsules

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By Application: Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Other Applications

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

North America was the largest region in the capecitabine market in 2022.

The table of contents in TBRC’s capecitabine market report includes:

1. Executive Summary

2. Capecitabine Market Characteristics

3. Capecitabine Market Trends And Strategies

4. Capecitabine Market - Macro Economic Scenario

5.Global Capecitabine Historic Market Size and Growth

.

32. Global Capecitabine Market Competitive Benchmarking

33. Global Capecitabine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Capecitabine Market

35. Capecitabine Market Future Outlook and Potential Analysis

36. Appendix

Learn About Us: 
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.

Contact Us: 
The Business Research Company 
Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293